Abiraterone-chem-structure (Abiraterone Tablets Civicascript Llc 1)
Abiraterone Tablet
Product Images NDC 82249-010
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Abiraterone (NDC 82249-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Civicascript, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Bl-250mg-120s (Abiraterone Tablets Civicascript Llc 7)
This is a description of a medication called Abiraterone Acetate. It comes in a tablet form containing 250mg of the medicine that should be swallowed whole and not chewed or crushed. There are 120 tablets in the container. The tablets are only for use by men and need to be kept out of the reach of children. There is a warning, forbidding women who are pregnant or may become so, to avoid handling the tablets without gloves, as indicated in its package insert. It is recommended to store the medicine at controlled room temperatures, between 15 °C to 30 °C. For complete information on the dosage, consult the accompanying product literature. The manufacturing company is located in Utah.*
Figure-1 (Image 01)
This appears to be a graph showing the "Time to death" in months for two groups: one that was given Abiraterone Acetate and another that was given a placebo. The % Survival is not available as it seems to be cut off.*
Figure-2 (Image 02)
This seems to be a table displaying information about "Subjects without Death" over a period of months from randomization, for two groups - "Abiraterone Acetate" and "Placebo". There are two columns for each month - one for each group, and the corresponding value represents the number of subjects without death. The data seems to be obtained through a clinical study, probably related to some treatment.*
Figure-3 (Image 03)
Figure-4 (Image 04)
This appears to be a chart or graph that shows data related to a study involving a treatment called Abiraterone acetate and a placebo. The X-axis is labeled in months from randomization and the Y-axis appears to show subjects at risk. The chart includes data for both treatments and shows the number of subjects at risk over the course of the study.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
